共同药业
(300966)
| 流通市值：11.57亿 | | | 总市值：17.75亿 |
| 流通股本：7513.23万 | | | 总股本：1.15亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 365,389,573.73 | 233,822,011.21 | 122,227,974.51 | 566,399,208.58 |
| 营业收入 | 365,389,573.73 | 233,822,011.21 | 122,227,974.51 | 566,399,208.58 |
| 二、营业总成本 | 407,868,913.77 | 250,301,029.55 | 122,389,251.15 | 542,210,044.28 |
| 营业成本 | 313,408,736.73 | 193,177,978.3 | 95,866,254.36 | 441,278,552.67 |
| 税金及附加 | 717,440.8 | 578,935.12 | 239,984.02 | 1,001,366.4 |
| 销售费用 | 4,678,374.09 | 2,470,416.38 | 864,906.68 | 7,064,563.48 |
| 管理费用 | 43,359,989.46 | 26,675,789.13 | 13,028,046.97 | 44,397,384.53 |
| 研发费用 | 32,233,458.68 | 20,278,578.57 | 9,505,034.39 | 38,098,898.41 |
| 财务费用 | 13,470,914.01 | 7,119,332.05 | 2,885,024.73 | 10,369,278.79 |
| 其中:利息费用 | 13,849,116.5 | 8,398,979.56 | 3,364,142.32 | 13,181,709.85 |
| 其中:利息收入 | 763,775.8 | 576,729.47 | 360,144.31 | 2,132,579.51 |
| 加:公允价值变动收益 | 0.05 | 0.05 | 0.05 | -11,867.23 |
| 加:投资收益 | 382,374.82 | 253,993.14 | -113,761.38 | 258,344.43 |
| 资产处置收益 | -226,823.44 | 27,178.67 | - | 168,297.3 |
| 资产减值损失(新) | 6,730,449.33 | 4,155,056.03 | -414,961.61 | -7,707,880.01 |
| 信用减值损失(新) | 1,483,124.03 | -1,341,850.4 | 771,670.79 | -4,573,951.66 |
| 其他收益 | 6,869,637.77 | 3,225,633.27 | 2,153,583.25 | 7,207,848.4 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -27,240,577.48 | -10,159,007.58 | 2,235,254.46 | 19,529,955.53 |
| 加:营业外收入 | 2,833,164.87 | 730,457.78 | 149,532.71 | 1,919,307.14 |
| 减:营业外支出 | 1,921,628.83 | 1,914,627.71 | 449,093.9 | 2,332,989.41 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -26,329,041.44 | -11,343,177.51 | 1,935,693.27 | 19,116,273.26 |
| 减:所得税费用 | -9,801,079.23 | -4,456,241.22 | -957,391.8 | -2,173,593.69 |
| 六、净利润 | -16,527,962.21 | -6,886,936.29 | 2,893,085.07 | 21,289,866.95 |
| 持续经营净利润 | -16,527,962.21 | -6,886,936.29 | 2,893,085.07 | 21,289,866.95 |
| 归属于母公司股东的净利润 | -14,162,211.34 | -5,118,586.73 | 3,547,307.04 | 23,005,014.76 |
| 少数股东损益 | -2,365,750.87 | -1,768,349.56 | -654,221.97 | -1,715,147.81 |
| (一)基本每股收益 | -0.12 | -0.04 | 0.03 | 0.2 |
| (二)稀释每股收益 | -0.12 | -0.04 | 0.03 | 0.2 |
| 九、综合收益总额 | -16,527,962.21 | -6,886,936.29 | 2,893,085.07 | 21,289,866.95 |
| 归属于母公司股东的综合收益总额 | -14,162,211.34 | -5,118,586.73 | 3,547,307.04 | 23,005,014.76 |
| 归属于少数股东的综合收益总额 | -2,365,750.87 | -1,768,349.56 | -654,221.97 | -1,715,147.81 |
| 公告日期 | 2024-10-24 | 2024-08-28 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |